Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has Global Blood Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GBT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: GBT's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: GBT underperformed the US Biotechs industry which returned 31.5% over the past year.
Return vs Market: GBT underperformed the US Market which returned 56.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Global Blood Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
1 month ago | Simply Wall StBreakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
2 months ago | Simply Wall StDid Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Is Global Blood Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GBT ($40.77) is trading below our estimate of fair value ($170.35)
Significantly Below Fair Value: GBT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GBT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GBT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GBT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GBT is overvalued based on its PB Ratio (6.1x) compared to the US Biotechs industry average (3.9x).
How is Global Blood Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: GBT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GBT's is expected to become profitable in the next 3 years.
Revenue vs Market: GBT's revenue (38.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: GBT's revenue (38.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (9.6%).
How has Global Blood Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GBT is currently unprofitable.
Growing Profit Margin: GBT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GBT is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare GBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: GBT has a negative Return on Equity (-59.49%), as it is currently unprofitable.
How is Global Blood Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: GBT's short term assets ($632.2M) exceed its short term liabilities ($79.0M).
Long Term Liabilities: GBT's short term assets ($632.2M) exceed its long term liabilities ($228.8M).
Debt to Equity History and Analysis
Debt Level: GBT's debt to equity ratio (35.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GBT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GBT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Global Blood Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GBT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ted Love (61 yo)
Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...
CEO Compensation Analysis
Compensation vs Market: Ted's total compensation ($USD10.10M) is above average for companies of similar size in the US market ($USD5.07M).
Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.
Experienced Management: GBT's management team is considered experienced (4.5 years average tenure).
Experienced Board: GBT's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Global Blood Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Global Blood Therapeutics, Inc.
- Ticker: GBT
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.484b
- Shares outstanding: 62.16m
- Website: https://www.gbt.com
Number of Employees
- Global Blood Therapeutics, Inc.
- 181 Oyster Point Boulevard
- South San Francisco
- United States
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an o...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/12 23:40|
|End of Day Share Price||2021/04/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.